2025-05-30 ワシントン大学セントルイス校
<関連情報>
- https://medicine.washu.edu/news/innovative-immunotherapy-shows-promise-against-aggressive-t-cell-cancers/
- https://ashpublications.org/blood/article/doi/10.1182/blood.2025028387/537566/Phase-1-2-Trial-of-Anti-CD7-Allogeneic-WU-CART-007
再発/難治性T細胞悪性腫瘍患者を対象とした抗CD7同種療法WU-CART-007の第1/2相試験 Phase 1/2 Trial of Anti-CD7 Allogeneic WU-CART-007 in patients with Relapsed/Refractory T-cell Malignancies
Armin Ghobadi,Ibrahim Aldoss,Shannon L. Maude,Deepa Bhojwani,Alan S. Wayne,Ashish Bajel,Bhagirathbhai Dholaria,Rawan G. Faramand,Ryan J Mattison,Anita W Rijneveld,C. Michel Zwaan,Friso G. Calkoen,André Baruchel,Nicolas Boissel,Michael P Rettig,Brent Wood,Kenneth Jacobs,Stephanie Christ,Haley Irons,Ben Capoccia,Deborah Masters,Justo Gonzalez,Tony Wu,Maria del Rosario,Alexander Hamil,Ouiam Bakkacha,John Muth,Brett Ramsey,Eileen McNulty,Jan Baughman,Matthew L Cooper,Jan K Davidson-Moncada,John F. DiPersio
Blood Published:May 30, 2025
DOI:https://doi.org/10.1182/blood.2025028387
Key Points
- WU-CART-007, an allogeneic fratricide resistant anti-CD7 CAR-T, established a manageable safety profile at the RP2D of 900 million cells.
- WU-CART-007 at the RP2D had a composite complete remission rate of 72.7% in heavily pretreated patients with relapsed/refractory T-ALL/LBL.
Relapsed/refractory T-cell acute lymphoblastic leukemia (ALL)/lymphoma (LBL) represent a significant unmet medical need. WU-CART-007 is a CD7-targeting, allogeneic, fratricide-resistant chimeric antigen receptor T cell product generated from healthy donor T cells. WU-CART-007 was evaluated in a phase 1/2 study with a 3+3 dose-escalation design followed by cohort expansion in relapsed/refractory T-ALL/LBL. Patients received one infusion of WU-CART-007 after standard or enhanced lymphodepleting chemotherapy. The primary objectives, to characterize safety and assess the composite complete remission rate, were met. Of 28 patients enrolled, 13 received the recommended phase 2 dose (RP2D) of 900 million cells of WU-CART-007 with enhanced lymphodepletion. The most common treatment-related adverse event was cytokine release syndrome (88.5%; 19.2% grade 3-4). Two grade 1 immune effector cell-associated neurotoxicity syndrome events (7.7%) and one grade 2 acute graft-vs-host disease event occurred (3.8%). One grade 2 immune effector cell associated HLH-like syndrome (IEC-HS) was observed. Among the 11 patients evaluable for response at the RP2D who received enhanced lymphodepleting chemotherapy, the overall response rate was 90.9% and composite complete remission rate was 72.7%. WU-CART-007 at the RP2D demonstrated a high response rate in patients with relapsed/refractory T-ALL/LBL and has the potential to provide a new treatment option. ClinicalTrials.gov registration: NCT04984356.
